• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

暴食障碍成人中用于暴食的耶鲁-布朗强迫量表的心理计量学分析和再验证。

A psychometric analysis and revalidation of the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating in adults with binge eating disorder.

机构信息

Shire, a member of the Takeda group of companies, Lexington, MA, USA.

Pharmerit International, Bethesda, MD, USA.

出版信息

Qual Life Res. 2019 Dec;28(12):3385-3394. doi: 10.1007/s11136-019-02277-8. Epub 2019 Aug 31.

DOI:10.1007/s11136-019-02277-8
PMID:31473907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6863951/
Abstract

PURPOSE

The Yale-Brown Obsessive Compulsive Scale modified for Binge Eating (Y-BOCS-BE) assesses the obsessiveness of binge eating thoughts and compulsiveness of binge eating behaviors. The findings of this study extend previously published Y-BOCS-BE psychometric evaluations in adults with binge eating disorder (BED).

METHODS

Data from three phase 3 lisdexamfetamine dimesylate studies in adults with BED (two randomized, double-blind, placebo-controlled short-term efficacy studies; one double-blind, placebo-controlled, randomized-withdrawal maintenance-of-efficacy study) were used. Psychometric evaluations included assessment of Y-BOCS-BE dimensionality, internal consistency, convergent validity, test?retest reliability, and determinations of clinically meaningful improvement using distribution- and anchor-based methods.

RESULTS

Domain specification analyses determined that the Y-BOCS-BE possessed a bifactor structure composed of a general binge eating severity domain and three subdomains (obsessive/compulsive, restraint, and control). Y-BOCS-BE internal consistency was maximized at week 12 (Cronbach?s ?, 0.95) and test?retest reliability was maximized in the 8-week retest interval from week 4 to week 12 across all no-change anchors (r?=?0.74?0.90). Likewise, convergent validity of the Y-BOCS-BE across all validators was maximized at week 12 (all r???0.66). Meaningful improvement for Y-BOCS-BE total scores was estimated to require score reductions of 12 to 17 points depending on the anchor.

CONCLUSIONS

The Y-BOCS-BE is a valuable tool for assessing BED symptoms. Maximization of Y-BOCS-BE reliability and validity at later study time points may be related to both treatment effects and improved insight into BED by participants during the study.

摘要

目的

耶鲁-布朗强迫量表修订版暴食分量表(Y-BOCS-BE)评估暴食思维的强迫性和暴食行为的强迫性。本研究的结果扩展了先前发表的暴食障碍(BED)成人 Y-BOCS-BE 心理测量评估。

方法

使用了三项成人 BED 的 lisdexamfetamine dimesylate 研究(两项随机、双盲、安慰剂对照的短期疗效研究;一项双盲、安慰剂对照、随机撤药维持疗效研究)的数据。心理测量评估包括 Y-BOCS-BE 维度、内部一致性、收敛效度、测试-重测信度以及使用分布和锚定方法确定临床有意义的改善。

结果

领域指定分析确定 Y-BOCS-BE 具有双因素结构,由一个一般暴食严重程度域和三个子域(强迫/强迫、克制和控制)组成。Y-BOCS-BE 的内部一致性在第 12 周达到最大值(Cronbach's α,0.95),并且在第 4 周到第 12 周的 8 周重测间隔内,所有不变锚的重测信度达到最大值(r=0.74-0.90)。同样,Y-BOCS-BE 在所有有效验证者中的收敛效度在第 12 周达到最大值(所有 r≥0.66)。根据锚的不同,Y-BOCS-BE 总分的有意义改善估计需要减少 12 到 17 分。

结论

Y-BOCS-BE 是评估 BED 症状的有效工具。在研究后期时间点,Y-BOCS-BE 的可靠性和有效性最大化可能与治疗效果以及参与者在研究期间对 BED 的洞察力提高有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73b1/6863951/16723bcbbfed/11136_2019_2277_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73b1/6863951/c400838faf35/11136_2019_2277_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73b1/6863951/16723bcbbfed/11136_2019_2277_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73b1/6863951/c400838faf35/11136_2019_2277_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73b1/6863951/16723bcbbfed/11136_2019_2277_Fig2_HTML.jpg

相似文献

1
A psychometric analysis and revalidation of the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating in adults with binge eating disorder.暴食障碍成人中用于暴食的耶鲁-布朗强迫量表的心理计量学分析和再验证。
Qual Life Res. 2019 Dec;28(12):3385-3394. doi: 10.1007/s11136-019-02277-8. Epub 2019 Aug 31.
2
Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.在两项针对患有暴饮暴食症的成年人的3期随机、双盲、安慰剂对照试验中,二甲磺酸赖右苯丙胺的疗效随时间变化情况。
Int J Eat Disord. 2017 Aug;50(8):884-892. doi: 10.1002/eat.22722. Epub 2017 May 8.
3
Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.二甲磺酸赖右苯丙胺对暴食症成年患者暴食行为及强迫和冲动特征的影响
Eur Eat Disord Rev. 2016 May;24(3):223-31. doi: 10.1002/erv.2418. Epub 2015 Dec 1.
4
Validation of the yale-brown obsessive compulsive scale modified for binge eating.暴食症耶鲁-布朗强迫量表修订版的验证。
Int J Eat Disord. 2015 Nov;48(7):994-1004. doi: 10.1002/eat.22407. Epub 2015 Jun 1.
5
Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.二甲磺酸赖右苯丙胺与安慰剂治疗暴食障碍成人的临床特征和治疗反应:按性别和年龄分析。
J Clin Psychiatry. 2019 Feb 26;80(2):18m12378. doi: 10.4088/JCP.18m12378.
6
Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies.两项III期研究中中度至重度暴饮暴食症成年人临床量表与暴饮暴食天数之间的关系。
Neuropsychiatr Dis Treat. 2018 Feb 15;14:537-546. doi: 10.2147/NDT.S158395. eCollection 2018.
7
Further psychometric properties of the Yale-Brown Obsessive Compulsive Scale - Second Edition.耶鲁-布朗强迫量表第二版的进一步心理测量特性。
Compr Psychiatry. 2016 Apr;66:96-103. doi: 10.1016/j.comppsych.2016.01.007. Epub 2016 Jan 20.
8
Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.二甲基磺酸赖右苯丙胺治疗暴饮暴食症:一项安慰剂对照试验
Hum Psychopharmacol. 2016 Sep;31(5):382-91. doi: 10.1002/hup.2547.
9
Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale.使用 Sheehan 残疾量表评估二甲磺酸赖右苯丙胺治疗暴食障碍的临床试验中的功能残疾。
Int J Methods Psychiatr Res. 2021 Mar;30(1):e1849. doi: 10.1002/mpr.1849. Epub 2020 Aug 25.
10
Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.赖氨酸安非他明治疗中重度暴饮暴食症成人患者的疗效:一项随机临床试验。
JAMA Psychiatry. 2017 Sep 1;74(9):903-910. doi: 10.1001/jamapsychiatry.2017.1889.

引用本文的文献

1
An exploratory study of associations between the ICD-11 personality disorder model and eating pathology.国际疾病分类第11版(ICD - 11)人格障碍模型与饮食病理学之间关联的探索性研究。
J Eat Disord. 2022 Aug 31;10(1):130. doi: 10.1186/s40337-022-00658-y.
2
Transdiagnostic phenotypes of compulsive behavior and associations with psychological, cognitive, and neurobiological affective processing.强迫行为的跨诊断表型及其与心理、认知和神经生物学情感处理的关联。
Transl Psychiatry. 2022 Jan 10;12(1):10. doi: 10.1038/s41398-021-01773-1.
3
Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.

本文引用的文献

1
Emotional processing in obesity: a systematic review and exploratory meta-analysis.肥胖中的情绪处理:系统评价和探索性元分析。
Obes Rev. 2018 Jan;19(1):111-120. doi: 10.1111/obr.12607. Epub 2017 Oct 10.
2
Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.赖氨酸安非他明治疗中重度暴饮暴食症成人患者的疗效:一项随机临床试验。
JAMA Psychiatry. 2017 Sep 1;74(9):903-910. doi: 10.1001/jamapsychiatry.2017.1889.
3
Social Cognition and Emotional Functioning in Patients with Binge Eating Disorder.
治疗暴食症新药的前景:精神病理学和神经药理学的见解。
J Psychopharmacol. 2022 Jun;36(6):680-703. doi: 10.1177/02698811211032475. Epub 2021 Jul 28.
暴饮暴食症患者的社会认知与情绪功能
Eur Eat Disord Rev. 2017 May;25(3):172-178. doi: 10.1002/erv.2504. Epub 2017 Feb 17.
4
Evaluating bifactor models: Calculating and interpreting statistical indices.评估双因子模型:计算和解释统计指数。
Psychol Methods. 2016 Jun;21(2):137-50. doi: 10.1037/met0000045. Epub 2015 Nov 2.
5
Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.用于治疗中重度暴饮暴食症成人患者的二甲磺酸赖右苯丙胺:两项关键3期随机对照试验结果
Neuropsychopharmacology. 2016 Apr;41(5):1251-60. doi: 10.1038/npp.2015.275. Epub 2015 Sep 9.
6
Validation of the yale-brown obsessive compulsive scale modified for binge eating.暴食症耶鲁-布朗强迫量表修订版的验证。
Int J Eat Disord. 2015 Nov;48(7):994-1004. doi: 10.1002/eat.22407. Epub 2015 Jun 1.
7
Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.治疗中重度暴食障碍成人的 lisdexamfetamine 的疗效和安全性:一项随机临床试验。
JAMA Psychiatry. 2015 Mar;72(3):235-46. doi: 10.1001/jamapsychiatry.2014.2162.
8
Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial.托莫西汀治疗暴饮暴食症:一项随机安慰剂对照试验。
J Clin Psychiatry. 2007 Mar;68(3):390-8. doi: 10.4088/jcp.v68n0306.
9
Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study.托吡酯治疗与肥胖相关的暴饮暴食症:一项安慰剂对照研究。
Biol Psychiatry. 2007 May 1;61(9):1039-48. doi: 10.1016/j.biopsych.2006.08.008. Epub 2007 Jan 29.
10
Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial.托吡酯治疗与肥胖相关的暴饮暴食症:一项随机、安慰剂对照试验。
Am J Psychiatry. 2003 Feb;160(2):255-61. doi: 10.1176/appi.ajp.160.2.255.